YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Mid-Term Outcome of Arteriovenous Fistula in Paediatric Patients With End-Stage Renal Disease: a Single Centre Experience

dc.authorscopusid 55371689300
dc.authorscopusid 57520221600
dc.contributor.author Şişli, E.
dc.contributor.author Gür, A.K.
dc.date.accessioned 2025-05-10T17:01:50Z
dc.date.available 2025-05-10T17:01:50Z
dc.date.issued 2019
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp Şişli E., Section of Pediatric Cardiovascular Surgery, Department of Cardiovascular Surgery, Van Education and Research Hospital, Van, Turkey; Gür A.K., Department of Cardiovascular Surgery, Van Yüzüncü Yıl University, Faculty of Medicine, Van, Turkey en_US
dc.description.abstract The aim of the study was to evaluate the patency rates of arteriovenous fistula (AVF) in paediatric patients with end-stage renal disease (ESRD) in the mid-term. The study was conducted retrospectively. The medical archive was searched between January 2015 and February 2018. A total of 26 patients comprised the study population. The median age and weight of the patients at the time of AVF creation were 13.2 years (IQR = 11.9 – 15.6 years) and 41.5 kg (34.8 – 50.5 kg), respectively. Eight (69.2%) patents were male. The AVF created was radio-cephalic in 21 (80.8%) and brachial-level in five (19.2%) patients; brachio-cephalic in 3 and brachio-basilic in 2 patients. The patients with a radial-level AVF were younger (p = 0.001), and their body weights were lower (p<0.001). In patients with radio-cephalic AVF, analysis of age (rs =-0.48, p = 0.028) and weight (rs =-0.56, p = 0.008) revealed a negative correlation with duration of AVF maturation. The duration of follow-up was 21.2 months (IQR = 14.5 – 28.3 months). While the primary rates at 1 and 2 years were 92.3% and 84.6%, the secondary patency rates were 96.2% and 92.3%, respectively. Our results showed that AVF is the most suitable and durable renal replacement therapy in patients with ESRD. The weight and level of AVF have a considerable influence on the duration of AVF maturation. In summary, AVF still remains the procedure of choice in regions where the paediatric kidney transplantation programmes are not completely set up that have resultant long transplantation waiting periods. © 2019, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved. en_US
dc.identifier.doi 10.5505/ejm.2019.27928
dc.identifier.endpage 134 en_US
dc.identifier.issn 1301-0883
dc.identifier.issue 2 en_US
dc.identifier.scopus 2-s2.0-85065816536
dc.identifier.scopusquality Q4
dc.identifier.startpage 130 en_US
dc.identifier.trdizinid 326416
dc.identifier.uri https://doi.org/10.5505/ejm.2019.27928
dc.identifier.uri https://hdl.handle.net/20.500.14720/5312
dc.identifier.volume 24 en_US
dc.identifier.wosquality N/A
dc.language.iso en en_US
dc.publisher Yuzuncu Yil Universitesi Tip Fakultesi en_US
dc.relation.ispartof Eastern Journal of Medicine en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Arteriovenous Fistula en_US
dc.subject End-Stage Renal Disease en_US
dc.subject Paediatrics en_US
dc.subject Vascular Surgical Procedures en_US
dc.title Mid-Term Outcome of Arteriovenous Fistula in Paediatric Patients With End-Stage Renal Disease: a Single Centre Experience en_US
dc.type Article en_US

Files